Approval of Adagrasib for KRAS G12C–Mutated NSCLC Will ‘Open Up Another Therapeutic Option’, Says Expert

Video

Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.

In an interview with CancerNetwork®, Alexander Spira, MD, PhD, FACP, a medical oncologist and co-director of the Virginia Cancer Specialists Research Institution, as well as the director of the Thoracic and Phase I Program and clinical assistant professor at Johns Hopkins University, spoke about the FDA’s accelerated approval of adagrasib (Krazati) for the treatment of patients with non–small cell lung cancer (NSCLC) harboring KRAS G12C mutations.

According to Spira, the approval of adagrasib allows for another treatment option for patients with KRAS G12C–mutated NSCLC who may tolerate the agent more than other approved therapies such as sotorasib (Lumakras). He also described other benefits of the agent in terms of managing central nervous system (CNS) metastases.

Transcript:

The approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer will open up another therapeutic option. As you know, we have sotorasib already approved, but [these agents] do have slightly different toxicity profiles. It's always good to have more than one class because some people do tolerate one better than the other one. It also verifies the fact that this is now an actual genetic mutation for which we've been trying to find drugs for the better part of a quarter century. The other thing that is that adagrasib does have some [central nervous system] CNS activity, and these patients do have a predilection to CNS metastases. Hopefully, it could be used in that situation for the right patients, although this would likely not be on the label.

Reference

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. News release. FDA. December 12, 2022. Accessed December 13, 2022. https://bit.ly/3UUVphS

Recent Videos
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Related Content